NantHealth (NASDAQ:NH) announced its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12), Bloomberg Earnings reports. NantHealth had a negative net margin of 188.81% and a negative return on equity of 54.16%. The company had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $23.30 million.
NH traded down $0.46 during midday trading on Thursday, reaching $3.08. The company’s stock had a trading volume of 126,336 shares, compared to its average volume of 52,034. The stock has a market cap of $382.24 million, a PE ratio of -2.75 and a beta of 0.19. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.26 and a current ratio of 2.28. NantHealth has a 1 year low of $3.05 and a 1 year high of $3.69.
NH has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of NantHealth from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Thursday, January 11th. BidaskClub upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Cowen restated a “buy” rating and issued a $4.50 price objective on shares of NantHealth in a report on Tuesday, March 20th. Jefferies Group set a $5.00 price objective on shares of NantHealth and gave the stock a “buy” rating in a report on Wednesday, March 21st. Finally, ValuEngine upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $4.69.
In other news, COO Ronald Allen Louks sold 7,095 shares of the stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $3.56, for a total transaction of $25,258.20. Following the sale, the chief operating officer now owns 89,690 shares in the company, valued at $319,296.40. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders sold 21,105 shares of company stock worth $70,440. Corporate insiders own 58.00% of the company’s stock.
NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.